

Greg Fenton Discusses ZenGUARD™ Antimicrobial Coating and Military Interest in Zentek's Aptamer Technology

written by InvestorNews | May 16, 2024

May 16, 2024 – In a recent interview with InvestorNews host Pat Bolland, Greg Fenton, CEO and Director of [Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN), discussed the company's innovative strides in nanotechnology and environmental sustainability, particularly focusing on their product ZenGUARD™. Developed in response to the pandemic, ZenGUARD™ is an antimicrobial coating designed to enhance the effectiveness of personal protective equipment (PPE) and HVAC filters. Fenton detailed the product's development timeline, noting that by fall 2020, ZenGUARD™ was 99.9% effective against SARS-CoV-2 and about 30 other pathogens. Highlighting a [case study](#) conducted with the City of Toronto, Fenton revealed that using ZenGUARD™-coated MERV 9 filters instead of MERV 13 filters could lead to annual cost savings of nearly \$40 million, significantly reduce carbon emissions, and decrease landfill waste by approximately 947 dumpsters. "Our aim is to help control infectious aerosols within existing HVAC systems without significantly increasing energy consumption and emissions," Fenton remarked.

Fenton also touched on the regulatory process, mentioning that while ZenGUARD™ is approved for use in surgical masks, it awaits approval from Health Canada's Pesticide Management Regulatory Agency for HVAC applications. Zentek is in the process of scaling up production to meet anticipated demand. "Based on the modeling that we've done and the value proposition associated

with it, this product is almost selling itself,” Fenton noted. Additionally, Zentek plans to initially sell directly to customers but aims to establish white-label agreements with HVAC manufacturers for broader market penetration. The conversation also explored Zentek’s [advancements](#) in aptamer technology through their subsidiary, Triera Biosciences, which is developing synthetic antibodies for various pathogens, including influenza and SARS-CoV-2. Fenton emphasized the potential for expedited military interest in their aptamer technology, given its rapid adaptability to emerging bio-threats.

To access the complete interview, [click here](#)

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company’s commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) filters. Zentek’s ZenGUARD™ production facility is in Guelph, Ontario.

To learn more about Zentek Ltd., [click here](#)

Disclaimer: Zentek Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. ("InvestorNews"), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this "presentation") does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or

results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company's profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.